173 related articles for article (PubMed ID: 37202499)
41. Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.
Berendsen MR; Stevens WBC; van den Brand M; van Krieken JH; Scheijen B
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260693
[TBL] [Abstract][Full Text] [Related]
42. Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma.
Elkourashy SA; Benkhadra M; Shafei L; Abujarir S; Ghasoub R
Clin Case Rep; 2024 May; 12(5):e8838. PubMed ID: 38721565
[TBL] [Abstract][Full Text] [Related]
43. More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma.
Ho C; Smith SD
Haematologica; 2024 Apr; 109(4):1022-1024. PubMed ID: 37794796
[No Abstract] [Full Text] [Related]
44. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma.
Singh AR; Gu JJ; Zhang Q; Torka P; Sundaram S; Mavis C; Hernandez-Ilizaliturri FJ
Cancer Metab; 2020; 8():10. PubMed ID: 32647571
[TBL] [Abstract][Full Text] [Related]
45. Pioneering cord blood transplantation in relapsed/refractory HIV-related lymphoma: A case study with concurrent intramuscular antiretroviral therapy.
Yokota T; Kurosawa S; Yoshimura Y; Bingo M; Yamaguchi T; Takada Y; So Y; Miyata N; Nakayama H; Sakurai A; Sato K; Ito C; Aisa Y; Nakazato T
Int J Infect Dis; 2024 Jun; ():107124. PubMed ID: 38838848
[TBL] [Abstract][Full Text] [Related]
46. Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
Izumiyama K; Inao T; Goto H; Harada S; Senjo H; Suto K; Hashiguchi J; Ogasawara R; Saga T; Igarashi T; Wakasa K; Kasahara I; Takeda Y; Yamaguchi K; Shigematsu A; Takahata M; Fujimoto K; Haseyama Y; Nagashima T; Sakai H; Kakinoki Y; Kurosawa M; Yokota I; Teshima T
Haematologica; 2024 Jun; ():. PubMed ID: 38867578
[TBL] [Abstract][Full Text] [Related]
47. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
Lv K; Kong F; Yu M; Zhou Y; Li F
Ann Hematol; 2024 Mar; 103(3):1017-1019. PubMed ID: 38155243
[No Abstract] [Full Text] [Related]
48. Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.
Chan JY; Somasundaram N; Grigoropoulos N; Lim F; Poon ML; Jeyasekharan A; Yeoh KW; Tan D; Lenz G; Ong CK; Lim ST
Discov Oncol; 2023 Jul; 14(1):132. PubMed ID: 37466782
[TBL] [Abstract][Full Text] [Related]
49. New treatment options in elderly patients with Diffuse Large B-cell Lymphoma.
Arcari A; Cavallo F; Puccini B; Vallisa D
Front Oncol; 2023; 13():1214026. PubMed ID: 37465115
[TBL] [Abstract][Full Text] [Related]
50. Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
Dada R
Cells; 2023 Jul; 12(14):. PubMed ID: 37508523
[TBL] [Abstract][Full Text] [Related]
51. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
Abdulhaq H; Hwang A; Mahmood O
Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
[TBL] [Abstract][Full Text] [Related]
52. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
53. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions.
Russler-Germain DA; Ghobadi A
Front Oncol; 2023; 13():1168622. PubMed ID: 37465110
[TBL] [Abstract][Full Text] [Related]
54. Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Sep; 102(9):2643-2644. PubMed ID: 37432417
[No Abstract] [Full Text] [Related]
55. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Thurner L; Ziepert M; Berdel C; Schmidt C; Borchmann P; Kaddu-Mulindwa D; Viardot A; Witzens-Harig M; Dierlamm J; Haenel M; Metzner B; Wulf G; Lengfelder E; Keller UB; Frickhofen N; Nickelsen M; Gaska T; Griesinger F; Mahlberg R; Marks R; Shpilberg O; Lindemann HW; Soekler M; Fischer von Weikersthal L; Kiehl M; Roemer E; Bentz M; Krammer-Steiner B; Trappe R; de Nully Brown P; Federico M; Merli F; Engelhard M; Glass B; Schmitz N; Truemper L; Bewarder M; Hartmann F; Murawski N; Stilgenbauer S; Rosenwald A; Altmann B; Schmidberger H; Fleckenstein J; Loeffler M; Poeschel V; Held G
Hemasphere; 2023 Jul; 7(7):e904. PubMed ID: 37427146
[TBL] [Abstract][Full Text] [Related]
56. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract][Full Text] [Related]
57. How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations.
Kambhampati S; Herrera AF; Rhee JW
JACC CardioOncol; 2023 Jun; 5(3):281-291. PubMed ID: 37397077
[TBL] [Abstract][Full Text] [Related]
58. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Birtas Atesoglu E; Gulbas Z; Uzay A; Ozcan M; Ozkalemkas F; Dal MS; Kalyon H; Akay OM; Deveci B; Bekoz H; Sevindik OG; Toptas T; Yilmaz F; Koyun D; Alkis N; Alacacioglu I; Sonmez M; Yavasoglu I; Tombak A; Mehtap O; Kurnaz F; Yuce OK; Karakus V; Turgut M; Kurekci DD; Ayer M; Keklik M; Buyuktas D; Ozbalak M; Ferhanoglu B
Hematol Oncol; 2023 Oct; 41(4):663-673. PubMed ID: 37211991
[TBL] [Abstract][Full Text] [Related]
59. Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax.
Perriello VM; Falini L; Ruggeri L; Sorcini D; Ballanti S; Flenghi L; Baffa N; Covarelli P; Sportoletti P; Pierini A; Falini B
EJHaem; 2023 May; 4(2):559-562. PubMed ID: 37206291
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
